A Phase 1 interventional study of CP-675,206 and CP-675,206 in Melanoma, sponsored by AstraZeneca. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tremelimumab in Melanoma — none open to participants now, none under way, none of them phase 3. tremelimumab · Melanoma.
Among the 12 studies testing tremelimumab in Melanoma, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 1, and was the 5th registered.
3,372 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →None of the 12 studies testing tremelimumab in Melanoma is open now. The open studies under Melanoma, anywhere →
tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tremelimumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 3 1
First in 2003; this study’s year is marked. 3 started in 2006.
This study's enrollment of 85 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 51 across the 12 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 6 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
20 studies in Melanoma by AstraZeneca: 2 open now, 3 under way, none of them phase 3. Of 17 finished, 2 (12%) have results posted.
Among the 20 studies in Melanoma by AstraZeneca, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2006, is one of 10 in phase 1, and was the 8th registered.
AstraZeneca’s Melanoma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing tremelimumab in Melanoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 20 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Commercial Formulation
Drug: CP-675,206
Current Formulation
Drug: CP-675,206
CP-675,206 15 mg/kg iv single dose on Day 1
Also known as: anti-CTLA4 human monoclonal antibody
CP-675,206 15 mg/kg iv single dose on Day 1
Pharmacokinetics: maximum plasma concentration of CP-675,206
Time frame: 1 hour
Pharmacokinetics: AUC, defined as the area under the concentration -time curve
Time frame: Time 0 to Day 85
Human-anti-human antibodies
Time frame: 1 year
Adverse events
Time frame: 1 year
Safety laboratory tests
Time frame: 1 year
Proportion of patients alive and free of disease at 1 year
Time frame: 1 year
The record gives a start of Jun 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tremelimumab